Company news

Avacta Group PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Second dose escalation in phase 1 trial of AVA6000

June 29, 2022

AffyXell expands partnership with GenScript ProBio

May 16, 2022

London Therapeutics headquarters established

May 11, 2022

Block Listing Application to AIM (update)

May 6, 2022

AffyXell milestone and increased equity stake

April 13, 2022

Poster presented at the AACR available to download

April 12, 2022

AffyXell partners with Biocytogen and KNTSC

April 8, 2022

AVA6000 data poster presentation at AACR

March 29, 2022

Directorate Change

March 21, 2022

Vimian acquires Avacta's Animal Health Division

March 16, 2022

Dose escalation in the phase I trial of AVA6000

February 3, 2022

Second pre|CISION Pro-drug Candidate Selected

January 18, 2022

Update on AffiDX and detection of Omicron variant

January 10, 2022

AffiDX Receives CE Mark for Consumer Self-Testing

December 22, 2021

Change of auditor

December 15, 2021

AffiDx® lateral flow test detects Omicron variant

December 15, 2021

FDA Approval of IND Application for AVA6000

November 29, 2021

Update on UK Availability of AffiDX Test

November 2, 2021

Interim Results for the Period Ended 30 June 2021

September 30, 2021

Development Milestone in LG Chem Partnership

September 29, 2021

New appointments to Scientific Advisory Board

September 6, 2021

Appointment of Chief Scientific Officer

September 2, 2021

First Patient Dosed in AVA6000 Phase 1 Trial

August 11, 2021

Update on AffiDX Lateral Flow Test

August 4, 2021

Diagnostics achieves ISO 13485 Certification

July 14, 2021

AffiDX Lateral Flow Test Detects Delta Variant

June 29, 2021

AffiDX Lateral Flow Test Distribution Agreement

June 21, 2021

Registration of AffiDX Lateral Flow Test in EU

June 11, 2021

Holding(s) in Company

June 9, 2021

MHRA Confirms Registration of Lateral Flow Test

June 7, 2021

Update on Lateral Flow Test Regulatory Submissions

June 1, 2021

Response to speculation

May 28, 2021

AffiDX SARS-CoV-2 Antigen Lateral Flow Test Update

May 10, 2021

Change of Nominated Adviser

May 6, 2021

Final Results

April 22, 2021

Clinical validation of AffiDX Lateral Flow Test

April 20, 2021

Distribution Agreement with ABCAM plc

April 6, 2021

Diagnostic Licensing Deal with Biokit

March 9, 2021

Rapid Antigen Test Detects SARS-CoV-2 Variants

March 8, 2021

Electronic Communications with Shareholders

March 3, 2021

Business Update

February 24, 2021

Re: Press Speculation

February 22, 2021

Phase I CTA for AVA6000 Approved by MHRA

February 18, 2021

Results of Initial Evaluation of SARS-CoV-2 LFT

February 16, 2021

Commercial Partnership with Mologic

February 8, 2021

AffyXell $7.3 Million Series A Financing

February 1, 2021

Collaboration Agreement with Bruker

January 28, 2021

License Agreement with POINT Biopharma Inc.

January 7, 2021

Submission of CTA for AVA6000 Pro-doxorubixin

December 23, 2020

License Agreement with Astrea Bioseparations

December 21, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 18 decks. Every deck is listed under its year.